| CRISPR Medicine | This is an overview of our interviews
Three research groups recently independently elucidated the genetic and epigenetic mechanisms driving prostate cancer metastasis. The innovative use...
GlaxoSmithKline Pharma’s Fiona Behan explores synthetic lethality and complex drivers of cancer to identify new therapeutic targets.
Two research groups are independently pioneering a groundbreaking gene-editing treatment for severe immunodeficiencies, potentially transforming the...
In a recent study, researchers in Germany used CRISPR/Cas9 nickases to develop a gene therapy approach, termed MILESTONE, to treat severe congenital...
In a recent study, researchers in Italy addressed the critical need for experimental validation of durable epigenetic silencing after transient...
Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...
Exploring the cutting edge of genetic engineering, the development of programmable recombinases and zinc finger domains is ushering in a new era of...
By targeting a highly conserved master controller sequence, Tune Therapeutics' lead candidate TUNE-401 can epigenetically silence all forms of the...